Loading...
On August 6, 2014, the FDA announced approval of oritavancin (Orbactiv), a glycopeptide antibiotic for treatment of acute bacterial skin and skin-structure infections (ABSSIs) in adults. In two phase III, randomized, controlled trials totaling >1900 patients, a single dose of oritavancin was noninferior to 7 to 10 days of vancomycin.
Oritavancin is administered intravenously as one 1200-mg dose over 3 hours. It has a long terminal half-life and does not require dose adjustment for mild/moderate hepatic or renal dysfunction. It can inhibit the metabolism of warfarin and also interferes with the coagulation tests used to monitor warfarin and heparin activity. The most common adverse effects seen in the clinical trials were headache, nausea, vo…